DISCO Pharmaceuticals GmbH’s Post

Applications for bispecific antibodies are emerging in various fields, including oncology, haematology, and diagnostics. With such a wide range of applications already, bsAbs are a particularly promising research tool. They're not limited to a particular field or therapy area, allowing researchers from all areas of the biotech industry to explore novel applications. In this article, my colleague, Desmond Schofield, discusses what the future could look like. #Antibodies #BispecificAntibodies #Oncology #Biotech

Radiomer Therapeutics, Inc., a company established by Fannin, is pioneering the development of targeted radiopharmaceuticals and radioligand therapies for theranostic applications. Our innovative approach leverages Fannin's proprietary Raptamer platform which has many unique features such as * Innovative Targeting Vector: Raptamers are based on a single-stranded (ss) DNA backbone with enhanced peptide-like side chains, which improve chemical diversity and increase binding affinity to targets. *Flexible Design: The modular nature of Raptamers allows for the attachment of various linkers, chelators, and isotope payloads, enabling the creation of customized therapeutic agents for specific medical uses. *Targeted Radiopharmaceuticals: High binding affinity allows Raptamers to deliver therapeutic radioisotopes, offering both diagnostic imaging and treatment capabilities. Raptamers deliver radioactive isotopes directly to diseased cells, reducing collateral damage to healthy tissues. By harnessing the unique properties of Raptamers, Radiomer Therapeutics aims to revolutionize personalized medicine and targeted therapy, addressing critical needs in diagnosing and treating various diseases. For more details: Please see the attached press release.

New: An experimental medicine from Summit Therapeutics, Inc. cut the risk of lung cancer progression in half when tested against the world’s most dominant immunotherapy, Merck & Co., Inc.’s KEYTRUDA® (pembrolizumab) HCP, in a clinical trial, according to data revealed at a highly anticipated presentation Sunday. Should further testing show a similar benefit, Summit’s drug, which is known as ivonescimab, has a chance to become a “new standard” over Keytruda for treating these patients, John Heymach, chair of thoracic, head and neck oncology at the MD Anderson Cancer Center, told BioPharma Dive. Details below: #WCLC24 #WCLC2024 #biotechnology #drugdiscovery #pharmaceuticals #lungcancer

In a Nature News Article earlier this year, it's clear that the radiopharma market is on the up, driven by the success of next-generation radiopharmaceuticals like Pluvicto and Lutathera. These innovative therapies, which deliver targeted radiation to cancer cells, are reshaping oncology by improving outcomes with fewer side effects. The potential for combining diagnostics and treatments in "theranostics" is particularly exciting, offering personalized, precise treatments. Pharma giants like Novartis and Eli Lilly are making billion-dollar acquisitions, signalling confidence in this field's future. With increased venture capital and dealmaking, radiopharmaceuticals are set to play a transformative role in cancer care.

OS Therapeutics’ tunable Antibody Drug Conjugate (tADC) candidate, OST-tADC-FRA-H, demonstrates strong antitumor activity in pre-clinical animal models of ovarian cancer. The folate receptor alpha (FRα)-targeting ADC uses pH-sensitive SiLinker™ technology to selectively release payloads within the acidic tumor microenvironment to reduce off-target toxicities. https://lnkd.in/gfaicnVe     Discovery supports innovative ADC research by offering clinical trial-ready, pathologist-driven biomarker assays, off-target toxicity and ADC linker stability assays, and assay-ready biospecimens. Learn more about our ADC capabilities here: https://lnkd.in/gA7nHFxD    #ADC #Oncology #Biomarkers 

Another milestone - small molecule screening is delivering results.

Our partners at the Ontario Centre of Innovation are celebrating Life Sciences Week by highlighting some of the amazing companies here in Ontario that are bringing cutting-edge solutions to patients all while growing the province’s life sciences sector and creating jobs. A great example of this success in the oncology space is the recent acquisition of Hamilton-based Fusion Pharmaceuticals by AstraZeneca in a deal worth up to $2.4 billion USD. The deal is allowing Fusion to further develop and manufacture its radiopharmaceuticals for the precision treatment of cancer, while continuing to contribute to the province’s economy. https://lnkd.in/dDmNsk-Y Victor Fedeli ONeconomy | ÉconomieON

Initial dose escalation results from its ongoing Phase 1 KisMET-01 study evaluating the investigational ‘next generation’ cMET-targeting Antibody-drug Conjugates (#ADC), #MYTX-011, in patients with previously treated, locally advanced or metastatic non-small cell lung cancer (#NSCLC) were presented at the annual meeting of the American Society of Clinical Oncology (#ASCO), held May 31st – June 4th, 2024. MYTX-011 is being developed by clinical-state biotech #Mythic Therapeutics. MYTX-011 is a novel #cMET-targeted Drug-to-antibody ratio (DAR) of 2 #vcMMAE* ADC with an #antibody that has been engineered to have pH-dependent binding, which results in higher internalization and #payload delivery to tumor cells with a range of cMET expression. ChemExpress provide #vcMMAE, #MMAE and many other payloads with high GMP quality. #ADCs #Payloads #Linkers #Linker-payload #GMP #Preclinical #Clinical #CDMO #FFS

New clinical data reveals breakthrough in cancer immunotherapy: Phio Pharmaceuticals Corp. to showcase INTASYL technology's potential in tumour treatment at SITC 2024. Learn how this innovation fights skin cancer. For daily news and analysis subscribe to the https://lnkd.in/gnuy4bKp newsletter. #Biopharma #Pharmaceuticals #Healthcare

Developed by #AI, Lantern Pharma Inc. (Nasdaq: LTRN)'s investigational #cancer drug LP-184 has received #FDA Fast-Track Designation for #glioblastoma, an aggressive form of #braincancer. #LP184, optimized using Lantern's AI platform #RADR®, bypasses GBM’s resistance to current treatments and shows promise in preclinical trials. If approved, LP-184 could become the first new glioblastoma treatment in over 20 years. https://lnkd.in/dpGxc499